Elixinol products launch in New Zealand following change in legislation

KEY TAKEAWAYS:

  • Elixinol products are now available to patients in New Zealand.
  • The launch of products in new Zealand comes following the change in legislation which removes CBD as a Class B1 controlled drug.
  • Patients may now import up to three months supply of CBD with prescriptions.

Elixinol Global Limited (ASX:EXL) is pleased to announce that Elixinol branded cannabidiol (CBD) products are now available on a prescription basis in New Zealand.

The launch of products in new Zealand comes following tthe passage of New Zealand’s Misuse of Drugs (Medicinal Cannabis) Amendment Act in December 2018, which classifies CBD with low levels of THC as prescription medicine and removes CBD as a Class B1 controlled drug.

The Act now recognises CBD as a substance with ‘therapeutic value with little or no psychoactive properties’.

Patients can now import up to three months worth of CBD products with a prescription.

Elixinol’s capsules, topicals and tinctures including liposomes meet the required standard for import into New Zealand.

Paul Benhaim, CEO of parent company EXL, said: ” Now, this change in New Zealand enables Elixinol to ship CBD to patients who have been requesting it for years.

We are delighted to be one of the first companies to supply New Zealand patients with the range our US customers have been benefiting from for years”.

 

About Elixinol Global Limited (ASX: EXL)

Elixinol Global Limited (ASX: EXL; OTCQX: ELLXF) through its businesses has a global presence in the cannabis industry including hemp-derived CBD dietary supplements, hemp food and wellness products, as well as cultivation and manufacture of medicinal cannabis products.

Register Interest